Therapeutics, Psychopharmacology & Mental Health Innovation
Session Overview
The treatment landscape for neurological and psychiatric conditions is undergoing one of the most significant periods of innovation in the history of medicine. After decades dominated by drugs that modulate monoamine neurotransmission and symptomatic management strategies of limited efficacy, the field is now witnessing the emergence of disease-modifying therapies in neurodegeneration, rapid-acting antidepressants that challenge foundational assumptions about how psychiatric drugs work, psychedelic-assisted therapies that are redefining the therapeutic relationship, and a new generation of neuromodulation technologies that can target neural circuits with unprecedented precision. This session is dedicated entirely to interventions, therapeutic mechanisms, and emerging treatment technologies across the full spectrum of neurological and psychiatric conditions — the counterpart to Session 2’s focus on disease mechanisms and pathophysiology.
This session features a keynote lecture, four oral presentations, and a poster presentation segment spanning pharmacological innovation, neuromodulation, digital therapeutics, clinical trial methodology in neuropsychiatry, and the regulatory and safety dimensions of emerging brain health treatments.
Why This Session Matters Now
Several developments are converging to make 2027 an exceptionally significant year for brain health therapeutics. The approval of anti-amyloid therapies in Alzheimer’s disease has opened a new chapter in disease-modifying neurology, while simultaneously revealing the complexity of translating biological efficacy into functional benefit and the challenges of biomarker-guided patient selection at scale. Ketamine and esketamine have demonstrated that rapid antidepressant effects — working through glutamatergic rather than monoaminergic mechanisms — are achievable, fundamentally expanding the theoretical framework of antidepressant drug development. Phase 2 and Phase 3 trials of psilocybin and MDMA-assisted therapy for treatment-resistant depression and PTSD are generating results that regulatory agencies are actively evaluating. Deep brain stimulation applications continue to expand, and transcranial magnetic stimulation protocols are achieving regulatory approval for new indications. Across every domain of brain health therapeutics, the pace of meaningful innovation has accelerated substantially.
Key Scientific & Technical Themes
Novel Pharmacotherapy — Antidepressants, Antipsychotics & Mood Stabilizers
The pharmacological treatment of mood and psychotic disorders is being transformed by mechanistic insights from neuroscience that are enabling development of agents acting on glutamatergic, GABAergic, cholinergic, and neuropeptide systems — targets that the dominant monoamine-focused paradigm largely neglected. Ketamine and its enantiomer esketamine, approved for treatment-resistant depression and demonstrating effects within hours rather than weeks, have provided proof of concept for NMDA receptor modulation as a therapeutic mechanism and catalyzed a broader investigation of glutamatergic pharmacology in mood disorders. New antipsychotic agents with novel receptor profiles — including muscarinic receptor agonists and trace amine-associated receptor modulators — are demonstrating antipsychotic efficacy with substantially improved metabolic and motor side effect profiles that could represent a genuine advance in tolerability. Pharmacokinetics, pharmacodynamics, and the prediction of treatment response using biomarker-guided approaches are becoming increasingly central to both drug development and clinical decision-making. This theme covers the clinical trial evidence, mechanistic rationale, and therapeutic development pipeline for next-generation psychopharmacology.
Psychedelic-Assisted Therapy, Ketamine & Emerging Rapid-Acting Treatments
The clinical investigation of psychedelic compounds — principally psilocybin, MDMA, and lysergic acid diethylamide — as adjuncts to structured psychotherapy represents one of the most scientifically and culturally significant developments in contemporary psychiatry. Randomized controlled trials of psilocybin-assisted therapy for treatment-resistant depression, major depressive disorder, and end-of-life existential distress have demonstrated effect sizes substantially exceeding those of conventional antidepressants, with a durability of response that appears to persist for months after a small number of treatment sessions. MDMA-assisted therapy for post-traumatic stress disorder has advanced through Phase 3 trials with compelling efficacy data, and regulatory review processes are actively evaluating the evidence. The neurobiological mechanisms by which psychedelic experiences produce durable psychological change — involving serotonergic receptor agonism, enhanced neuroplasticity, disruption of default mode network activity, and facilitation of psychotherapeutic processes — are the subject of intense investigation. This theme examines the clinical evidence, mechanistic biology, therapeutic protocols, and regulatory status of psychedelic-assisted therapies and other rapid-acting treatment approaches.
Neuromodulation — TMS, tDCS, Deep Brain Stimulation & Closed-Loop Systems
Non-invasive and invasive neuromodulation technologies are expanding the therapeutic options available for neurological and psychiatric conditions where pharmacotherapy is insufficient, intolerable, or contraindicated. Transcranial magnetic stimulation has demonstrated clinical efficacy in depression, OCD, and migraine, with accelerated theta-burst stimulation protocols enabling delivery of effective treatment in a fraction of the time previously required. Transcranial direct current stimulation is being investigated across a range of indications including depression, pain, cognitive rehabilitation, and neuromotor recovery, with ongoing questions about optimal stimulation parameters and inter-individual variability in response. Deep brain stimulation has established therapeutic roles in Parkinson’s disease, dystonia, and tremor, and is under investigation for treatment-resistant depression, OCD, and Alzheimer’s disease, with the development of adaptive and closed-loop systems that adjust stimulation parameters in real time based on neural biomarkers representing a major technological advance. This theme covers the clinical evidence, technological development, and neural circuit mechanisms of non-invasive and invasive neuromodulation across neurological and psychiatric indications.
Digital Therapeutics, Telepsychiatry & Precision Mental Health
Digital therapeutics — software-based interventions that deliver evidence-based psychological treatments through smartphone applications, web platforms, and virtual reality environments — are creating new modalities for extending mental health treatment to populations with limited access to specialist care. Regulatory approval of digital therapeutics for depression, anxiety, substance use, and insomnia in multiple jurisdictions has validated the clinical evidence base and created a framework for reimbursement that is accelerating adoption. Telepsychiatry has demonstrated non-inferior outcomes to in-person care for a range of conditions while substantially improving access, particularly in rural and underserved populations, and is increasingly integrated into standard mental health service delivery. Precision psychiatry — the use of biomarker, genetic, neuroimaging, and clinical data to guide individualized treatment selection — is advancing toward clinical implementation, with prediction models for antidepressant response, side effect risk, and relapse probability beginning to achieve accuracy sufficient for clinical utility. This theme examines the evidence base, implementation science, and technological development of digital and precision therapeutic approaches in mental health.
Clinical Trials, Treatment Response Biomarkers & Regulatory Frameworks in Neuropsychiatry
The design and conduct of clinical trials in neuropsychiatry presents methodological challenges that are distinct from other medical specialties — including the heterogeneity of diagnostic categories, the importance of placebo response, the complexity of assessing subjective symptom outcomes, and the long timelines required to demonstrate disease modification. Treatment response biomarkers — biological measures that predict or track response to specific therapeutic interventions — are increasingly integrated into trial design as enrichment strategies, stratification variables, and pharmacodynamic endpoints, with the potential to substantially improve trial efficiency and the probability of detecting true therapeutic signals. Safety monitoring, adverse effect characterization, and long-term outcome assessment are particularly important in neuropsychiatric trials, where treatment effects on cognition, mood, and behavior require careful evaluation. The regulatory landscape for neuropsychiatric drugs and medical devices is evolving in response to the novel mechanisms and delivery formats of emerging treatments, with adaptive trial designs, patient-reported outcomes, and digital endpoint technologies gaining traction in regulatory guidance. This theme covers clinical trial methodology, biomarker-guided trial design, safety science, and the regulatory frameworks governing neuropsychiatric therapeutic development.
Research Landscape & Data Trends
Neuropsychiatric therapeutics is experiencing a renaissance of innovation after a prolonged period of limited mechanistic progress, driven by the convergence of new biological targets, novel delivery systems, and a regulatory environment increasingly receptive to adaptive and biomarker-guided development strategies. The psychedelic therapy literature has expanded rapidly from small proof-of-concept studies to adequately powered Phase 2 and 3 trials, generating data that is reshaping the regulatory conversation around mental health drug development. Neuromodulation research has been transformed by the introduction of accelerated stimulation protocols and the development of closed-loop and adaptive stimulation systems. The digital therapeutics literature is maturing, with an increasing proportion of registered trials and regulatory submissions providing the evidentiary standard required for clinical adoption. By 2027, precision treatment selection using multi-modal biomarkers, the neuroscience of psychedelic-induced neuroplasticity, and the long-term outcomes of disease-modifying interventions in neurodegeneration are expected to represent the most consequential areas of therapeutic research.
Who Should Attend
- Psychiatrists and neurologists prescribing and evaluating pharmacological treatments for brain health conditions
- Clinical researchers and trialists designing and conducting neuropsychiatric drug and device trials
- Psychopharmacologists and neuroscientists investigating the mechanisms of existing and emerging therapeutic agents
- Neuromodulation specialists and biomedical engineers working on TMS, tDCS, DBS, and closed-loop stimulation systems
- Psychedelic therapy researchers, therapists, and clinical scientists contributing to the evidence base for psychedelic-assisted treatment
- Digital therapeutics developers and clinical researchers evaluating software-based mental health interventions
- Pharmacokineticists, clinical pharmacologists, and drug safety scientists working in neuropsychiatric drug development
- Regulatory scientists and health technology assessment professionals evaluating neuropsychiatric therapeutic approvals
- Precision medicine researchers developing biomarker-guided treatment selection strategies for neurological and psychiatric conditions
- Mental health service researchers and implementation scientists translating therapeutic advances into accessible clinical practice
Session Perspective
Brain health therapeutics is at an inflection point where the convergence of mechanistic biology, technological innovation, and regulatory evolution is creating genuine opportunity for treatments that go beyond symptom management toward disease modification, durable recovery, and individualized precision. The session reflects the conviction that this opportunity can only be realized through the highest standards of clinical trial methodology, rigorous biomarker science, transparent reporting of safety and efficacy data, and a commitment to ensuring that advances in brain health treatment reach those who need them most. Researchers, clinicians, and developers who are building the evidence base for the next generation of brain health therapeutics are invited to contribute to this conversation.
If your research aligns with this session, we invite you to submit an abstract for consideration.
